多发性骨髓瘤患者外周血清中microRNA-181a和microRNA-20a表达水平的检测及其临床意义

doi:10.13481/j.1671-587x.20150336

Abstract

Abstract:

Objective To investigate the expression levels of serum microRNA-181a and microRNA-20a in the patients with multiple myeloma (MM), and to explore the clinical significances of microRNA-181a and microRNA-20a in the occurrence and development of MM. Methods 32 patients with M and 12 patients with other blood diseases, from Department of Hematology of First Affiliated Hospital, School of Medical Sciences, Xi'an Jiaotong University, during 2013.01-2014.05, were chosen.All the subjects accorded with the diagnostic criteria from Blood Disease Diagnosis and Curative Effect of Standard, excluding anybody who was in a stable condition with other organ failure such as heart, lung, and liver.And at the same time, 20 healthy subjects were selected as control group.The expression levels of microRNA-181a and microRNA-20a in serum of the patients with MM, the patients with other disease and healthy individuals were examined by Real-time polymerase chain reaction (Real-time PCR).The serum β2 microglobulin (β2- MG) levels, lactate dehydrogenase (LDH) activities, albumin (ALB) levels, free light chain (FLC) levels and M protein percentages were detected at the same time in three groups, and then the differences were compared. Results The expression levels of serum microRNA-181a and microRNA-20a in three groups were 0.0452 and 5.879, 0.000 and 0.072, 0.004 and 1.159, respectively;the differences showed statistically signiifcance(H=15.218, 9.891;P=0.000, 0.007).The differences between MM group and normal control group were statistically significant (Z=-2.702, -1.979;P=0.005, 0.048) and the differences between MM group and other blood diseases group were also statistically significant (Z=-3.163, -2.722;P=0.001, 0.005).The expression levels of microRNA-181a and microRNA-20a were positively correlated with the M protein percentage(r=0.574, 0.739;P=0.032, 0.003);the expression level of microRNA-181a was positively related with the serum β2-MG and serum free FLC levels(r=0.552, 0.780;P=0.041, 0.001). Conclusion The microRNA-181a and microRNA-20a highly express in the serum of the patients with MM, which suggests that microRNA-181a and microRNA-20a might play a role in the development of MM and they may become the diagnosis markers of MM;microRNA-181a is expected to be an index to predict the poor prognosis of MM.

Key words: microRNA-181a, microRNA-20a, multiple myeloma, Real-time polymerase chain reaction

CLC Number:

R733.3

PENG Jing, YUAN Ruili, WANG Xiaoqin, WU Feng, GUO Xuan. Detection of expression levels of microRNA-181a and microRNA-20a in serum of patients with multiple myeloma and its clinical significance[J].Journal of Jilin University Medicine Edition, 2015, 41(03): 625-630.

References

[1] Turner ML, Schnorfeil FM, Brocker T.MicroRNAs regulate dendritic cell differentiation and function[J].J Immunol, 2011, 187 (8):3911-3917.

[2] Leone E, Morelli E, Tassone P, et al.Targeting microRNA-21 inhibits in vitro and in vivo multiple myeloma cell growth[J].Clin Cancer Res, 2013, 19(8):2096-2106.

[3] Pichiorri F, Suh SS, Rocci A, et al.Downregulation of p53-inducible microRNAs 192, 194and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development[J].Cancer Cell, 2010, 18(4):367-381.

[4] Zhang W, Wang YE, Zhang Y, et al.Global epigenetic regulation of microRNAs in multiple myeloma[J].PLoS One, 2014, 9(10):e110973.

[5] Pons A, Nomdedeu B, Navarro A, et al.Hematopoiesis-related microRNA expression in myelodysplastic syndromes[J].Leuk Lymphoma, 2009, 50(11):1854-1859.

[6] Chen CZ, Li L, Lodish HF, et al.MicroRNAs modulate hematopoietic lineage differentiation[J].Science, 2004, 303(5653):83-86.

[7] Yyusnita Y, Norsiah MD, Zakiah I, et al.MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray[J].Malays J Pathol, 2012, 34(2):133-143.

[8] Lionetti M, Agnelli L, Mosca L, et al.Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated microRNA expression associated with allelic imbalances and gene expression profiles[J].Genes Chromosomes Cancer, 2009, 48(6):521-531.

[9] Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al.Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders[J].Blood Cancer J, 2012, 2(1):e53.

[10] Xiao C, Srinivasan L, Calado DP, et al.Lymphoproliferative disease and autoimmunity in mice with increased microRNA17-92 expression in lymphocytes[J].Nature Immunol, 2008, 9(4):405-414.

[11] Lee SK, Calin GA.Non-coding RNAs and cancer:new paradigms in oncology[J].Discov Med, 2011, 11(58):245-254.

[12] Yang X, Liang L, Zhang XF, et al.MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway[J].Hepatology, 2013, 58(1):158-170.

[13] Ahmad A, Maitah MY, Ginnebaugh KR, et al.Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating microRNAs[J].J Hematol Oncol, 2013, 6(1):77-86.

[14] Nishida N, Nagahara M, Sato T, et al.Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic microRNA clusters[J].Clin Cancer Res, 2012, 18(11):3054-3070.

[15] Song SD, Zhou J, Zhou J, et al.MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma[J].Oncol Lett, 2013, 6(4):953-959.

[16] Cui B, Chen L, Zhang S, et al.MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia[J].Blood, 2014, 124(4):546-554.

[17] Qu X, Zhao M, Wu S, et al.Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma[J].Med Oncol, 2014, 31(10):e219.

[18] Luo X, Gu J, Zhu R, et al.Integrative analysis of differential miRNA and functional study of microRNA21 by seed-targeting inhibition in multiple myeloma cells in response to berberine[J].BMC Syst Biol, 2014, 8(1):82-91.

Detection of expression levels of microRNA-181a and microRNA-20a in serum of patients with multiple myeloma and its clinical significance

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Metrics

Comments

Recommended 0

[1]	WANG Chong, HAO Zheng, LIU Weiming, ZHAO Conghai, ZHANG Jinnan. Epidural hematoma ossification after craniocerebral injury: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 628-630.
[2]	HUANG Qi, SHA Hui, CHEN Long, LYU Longlong, XU Shengming, ZHANG Zetian, ZHAO Song, JIN Fengyan, NIU Feng. Expression levels of plasma lncRNA MALAT1, LincRNA-p21 and GAS5 in patients with multiple myeloma and chronic lymphocytic leukemia and their diagnostic significances [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 339-345.
[3]	ZHEN Yong-zhan,JI Chun-mei,ZHAO Yu-fang,YAN Feng,LIU Xue-jun,WANG Mei-mei,XU Ai-jun. Apoptosis-induction of lidamycin in human multiple  myeloma SKO-007 cells enhanced by bortezomid through endoplasmic reticulum stress pathway [J]. Journal of Jilin University Medicine Edition, 2013, 39(6): 1206-1210.
[4]	WANG Xue-mei\|CUI Jiu-wei\|XIAO Zhong-ping\|CHEN Lin\|GAO Peng\|FU Kun\|. Comparison of clinical efficacy between MPT and MP in elderly patients with multiple myeloma  [J]. J4, 2012, 38(5): 999-1002.